Product
nedosiran
Aliases
DCR-PHXC
Name
RIVFLOZA
INN Name
nedosiran
FDA Approved
Yes
1 clinical trial
1 organization
4 indications
1 document
Indication
Primary HyperoxaluriaIndication
Primary Hyperoxaluria Type 1Indication
Primary Hyperoxaluria Type 2Indication
Primary Hyperoxaluria Type 3Clinical trial
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal FunctionStatus: Recruiting, Estimated PCD: 2024-12-01
Document
DailyMed Label: RIVFLOZAOrganization
Novo Nordisk